KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accounts Payables: 2010-2024

Historic Accounts Payables for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $60.9 million.

  • Emergent BioSolutions' Accounts Payables fell 30.09% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 million, marking a year-over-year decrease of 30.09%. This contributed to the annual value of $60.9 million for FY2024, which is 45.72% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Accounts Payables of $60.9 million as of FY2024, which was down 45.72% from $112.2 million recorded in FY2023.
  • Emergent BioSolutions' Accounts Payables' 5-year high stood at $136.1 million during FY2020, with a 5-year trough of $60.9 million in FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $103.5 million (2022), whereas its average is $92.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 43.57% in 2020, then slumped by 45.72% in 2024.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Accounts Payables stood at $136.1 million in 2020, then fell by 5.29% to $128.9 million in 2021, then declined by 19.71% to $103.5 million in 2022, then grew by 8.41% to $112.2 million in 2023, then plummeted by 45.72% to $60.9 million in 2024.